Trial reportInternational urology and nephrology2026
Efficacy of daily silodosin 8 mg as a potential reversible male contraceptive: A prospective placebo controlled study.
Trial report in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Alpha-Adrenoceptor Blockade as a Novel Pathway Toward Non-Hormonal Male Contraception: A Mechanistic and Clinical Evidence Review.Journal of clinical medicine · 2026Review
- Endoscopic combined intrarenal surgery (ECIRS) versus supine percutaneous nephrolithotomy (S-PCNL): a propensity score matched study of surgical outcomes and complications.World journal of urology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the efficacy of silodosin 8 mg as potentially reversible male contraceptive.
methodsIn all, 200 healthy, sexually active, fertile male candidates were assigned as follows: 100 in silodosin group and 100 in placebo group. Males using other contraceptive methods were excluded. Follow up data of total spermatozoa per ejaculate, semen volume and post-ejaculation urinalysis after 2, 6 and 12 weeks of the studied groups were recorded. The various side effects reported in the study groups after 12 weeks from the start of the study were recorded.
main outcome measuresThe primary outcome measure was the treatment period and pregnancy rate during the study to evaluate silodosin contraceptive efficacy. The secondary outcome measure was intolerance to the drug due to adverse events leading to dropping out of the study.
resultsAfter 3 months, total spermatozoa per ejaculate and semen volume in silodosin group were 0.113 ± 0.480 (0.0003-3.1) and 0.600 ± 0.028 (0.55-0.64) respectively that were highly significantly decreased compared to placebo group 75.967 ± 5.105 (66.4-85.90) and 2.415 ± 0.278 (1.99-3.03) respectively, p < 0.001. Side effects in the study groups after 3 months, silodosin group significantly suffered from stuffy nose, dizziness, weakness and scanty ejaculate (26%, 17%, 15% and 84%, respectively) higher than placebo group (4%, 2%, 4% and 6%, respectively), with highly significant difference between groups, p < 0.001, < 0.001, 0.008 and < 0.001, respectively). Silodosin group significantly had lower pregnancy incidence (4%) compared to placebo group (17%), p < 0.001.
conclusionSilodosin 8 mg yields a better sperm suppression results as on-demand male contraception after 3 months of continuous daily oral intake when compared to placebo, associated with pregnancy rate of 4% and higher but tolerable side effects.
Indexed as
Identifiers
41269482What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.